Publications by authors named "N Harbeck"

Claim this Profile
E
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.
Evert S M van Aken, Ajeet Kumar Gandhi, Sean M O'Cathail, Gerben Borst, Jorge Barriuso, Nadia Harbeck

Radiother Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial.
K L Jhaveri, P Neven, M L Casalnuovo, S-B Kim, E Tokunaga, N Harbeck

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.
Hope S Rugo, David W Cescon, Mark E Robson, Seock-Ah Im, Florence Dalenc, Nadia Harbeck

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al.
Oleg Gluz, Ronald Kates, Sherko Kuemmel, Ulrike Nitz, Nadia Harbeck

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons.
F André, D Soldato, I Vaz-Luis, A Cervantes, S Peters, N Harbeck

ESMO Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis